Who we are
Worldwide experts from academia and industry endorsing Novadiscovery’s approach.
What we do
For streamlined target identification & secured proof of concept.
What we do
Clinical insights & strategy
A digital sandbox to optimize trial design and capture best responders.
How we do it
The WISE engine
To ensure full traceability from a simulation output back to each primary source and avoid the black box syndrome.
How we do it
The effect model
The result of decades of experience in clinical trials methodology, the Effect Model law has solved the main problem plaguing the development of in silico clinical trials: the paradigm of efficacy.
We’re constantly on the hunt for the most talented individuals in our industry. If you have a knack for the development of mathematical and computational models of biological systems or if you are a genius developer with a keen interest in working on a state-of-the-art platform, fill the application form.
Beaucoup d’arguments militent en faveur du in silico en complément et en renforcement mais non en remplacement des recherches in vitro et in vivo.
September 4, 2018, 15.00-17.00
European Parliament, Brussels, Belgium
In vivo, in vitro, in silico: Why computer modelling is the next evolution of the healthcare sector.
The collective work of Avicenna members, including Novadiscovery, will be showcased.
Totem HealthTech organisé par BpifranceHub : Dans quelle mesure intégrer l’IA dans le parcours de soin ?
François-Henri BOISSEL est invité lors du Totem HealthTech de BpifranceHub aux côtés de @therapixel et du Dr Jean Sébastien Hulot
September 5-7, 2018
Evgueni Jacob, biostatistician at Novadiscovery, will give an oral presentation on “An in silico HBV model predicts viral response to the oral non-steroidal carboxylic acid FXR agonist EYP001a” at the VPH conference 2018, Saragoza, Spain.
PAGE 2018 Meeting: An in silico model of Hepatitis B virus predicts patients response to ENYO PHARMA’s drug candidate EYP001
NOVADISCOVERY presents first results from the in silico component of the exploratory clinical program initiated by ENYO Pharma on EYP001, a non-bile acid FXR receptor agonist currently in phase 1b trial for the treatment of chronic Hepatitis B.
It is now important for the European Medicines Agency to recognize and integrate into its regulatory processes these new methods of in silico simulation and prediction.
to accelerate the clinical development of drug candidate EYP001.
October 2, 2017
François-Henri BOISSEL introducing NOVA at Labiotech Refresh 2017, Berlin.